Chiesi Group to Acquire KalVista Pharmaceuticals for Approximately $1.9 Billion

Intelligence Brief:Chiesi Group to Acquire KalVista Pharmaceuticals for Approximately $1.9 BillionBolstering Rare Disease PortfolioGilead Sciences Completes $7.8 Billion Acquisition of ArcellxEnhancing CAR T-cell Therapy PipelineTeva Pharmaceuticals to Acquire Emalex Biosciences for Up to $900 MillionExpanding Neuroscience PortfolioUChicago Medicine Partners with Artisight for Enterprise-Wide Smart Hospital Platform DeploymentCCS Becomes First Chronic Care Management Organization to Deploy Enterprise-Wide Agentic AI**(INTRO MUSIC: Upbeat, fast-paced, tech-infused synth-pop. Fades slightly as hosts begin.)** **Alex:** Welcome to Healthcare Daily Pulse, your rapid-fire dive into the data shaping tomorrow's health economy. I'm Alex, dissecting the P&L impact and implementation friction. **Sam:** And I'm Sam, tracking the market shifts and strategic plays, always with an eye on the competitive landscape. Let's get straight to it. First up, a significant move in the rare disease space. --- **SEGMENT 1: Chies...